FBRX vs MRK
Forte Biosciences, Inc. vs Merck & Co. — AI-powered side-by-side comparison
FBRX
Forte Biosciences, Inc.
59
Watch
VS
| Metric | FBRX | MRK |
|---|
| AI Score |
59
|
70
|
| Price |
$76.88
|
$130.34
|
| P/E Ratio |
-16.78×
|
103.53×
|
| ROE |
-113.7%
|
34.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
75.4%
|
| Debt / Equity |
0.00×
|
1.29×
|
| Dividend Yield |
0.0%
|
2.6%
|
| RSI (14) |
85.6
|
64.5
|
| Beta |
2.645
|
0.207
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for FBRX versus MRK.
MRK leads by 11 points.
MRK scores 70/100 (Buy) versus FBRX at 59/100 (Watch).
FBRX Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 80.8% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 86 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 92 -- overbought on the larger timeframe too — Technical
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical